Belpointe Asset Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Belpointe Asset Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-186	Closed	-$20K	–	3679
2023 Q1	$20K	Buy	186 +154	+481%	+$17.7K	﹤0.01%	2311
2022 Q4	$3.52K	Buy	+32	New	+$2.08K	﹤0.01%	3054

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Belpointe Asset Management's RXDX Position: Q2 2023 in Review

Belpointe Asset Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 186 shares — an estimated $20K sold.

Belpointe Asset Management first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $20K in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Belpointe Asset Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Belpointe Asset Management sold 186 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $20K.
Belpointe Asset Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Belpointe Asset Management's Prometheus Biosciences, Inc. Common Stock position peaked at $20K in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.